Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression
作者： Katsuaki Sato , Kenichi Suda , Shigeki Shimizu , Kazuko Sakai , Hiroshi Mizuuchi
DOI: 10.1371/JOURNAL.PONE.0154186
关键词: Pathology 、 Biology 、 Adenocarcinoma of the lung 、 Anaplastic lymphoma kinase 、 Gene mutation 、 Gefitinib 、 Tyrosine kinase 、 Adenocarcinoma 、 Receptor tyrosine kinase 、 KRAS 、 General Biochemistry, Genetics and Molecular Biology 、 General Agricultural and Biological Sciences 、 General Medicine
摘要: The receptor tyrosine kinase AXL is a member of the Tyro3-Axl-Mer subfamily. affects several cellular functions, including growth and migration. aberration reportedly marker for poor prognosis treatment resistance in various cancers. In this study, we analyzed clinical, pathological, molecular features expression lung adenocarcinomas (LADs). We examined 161 LAD specimens from patients who underwent pulmonary resections. When protein was quantified (0, 1+, 2+, 3+) according to immunohistochemical staining intensity, results were 0: 35%; 1+: 20%; 2+: 37%; 3+: 7% samples. status did not correlate with clinical features, smoking pathological stage. However, whose showed strong (3+) had markedly poorer prognoses than other groups (P = 0.0033). Strong also significantly associated downregulation E-cadherin 0.025) CD44 0.0010). addition, 9 12 driver gene mutations (6 EGFR, 2 KRAS, 1 ALK). conclusion, found that surgically resected LADs predictor prognosis. characterized by mesenchymal status, higher stem-cell-like markers, frequent mutations.
harvard.edu
sci-hub.se 参考文章(33)
Juliano D Paccez, Matjaz Vogelsang, M Iqbal Parker, Luiz F Zerbini, None, The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. International Journal of Cancer. ,vol. 134, pp. 1024- 1033 ,(2014) , 10.1002/IJC.28246
Kazuko Sakai, Shinsuke Kazama, Yuzo Nagai, Koji Murono, Toshiaki Tanaka, Soichiro Ishihara, Eiji Sunami, Shuta Tomida, Kazuto Nishio, Toshiaki Watanabe, Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions. Oncotarget. ,vol. 5, pp. 9641- 9649 ,(2014) , 10.18632/ONCOTARGET.2438
Song Yi Bae, Ji-Young Hong, Hye-Jung Lee, Hyen Joo Park, Sang Kook Lee, Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer Oncotarget. ,vol. 6, pp. 10146- 10160 ,(2015) , 10.18632/ONCOTARGET.3380
William D Travis, Elisabeth Brambilla, Allen P Burke, Alexander Marx, Andrew G Nicholson, None, Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. Journal of Thoracic Oncology. ,vol. 10, pp. 1240- 1242 ,(2015) , 10.1097/JTO.0000000000000663
Yan-Long Yang, Ming-Wu Chen, Lei Xian, Prognostic and Clinicopathological Significance of Downregulated E-Cadherin Expression in Patients with Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis PLoS ONE. ,vol. 9, pp. e99763- ,(2014) , 10.1371/JOURNAL.PONE.0099763
Peng Cheng, Emma Phillips, Sung-Hak Kim, David Taylor, Thomas Hielscher, Laura Puccio, Anita B. Hjelmeland, Peter Lichter, Ichiro Nakano, Violaine Goidts, Kinome-wide shRNA Screen Identifies the Receptor Tyrosine Kinase AXL as a Key Regulator for Mesenchymal Glioblastoma Stem-like Cells Stem cell reports. ,vol. 4, pp. 899- 913 ,(2015) , 10.1016/J.STEMCR.2015.03.005
Takashi Kohno, Hitoshi Ichikawa, Yasushi Totoki, Kazuki Yasuda, Masaki Hiramoto, Takao Nammo, Hiromi Sakamoto, Koji Tsuta, Koh Furuta, Yoko Shimada, Reika Iwakawa, Hideaki Ogiwara, Takahiro Oike, Masato Enari, Aaron J Schetter, Hirokazu Okayama, Aage Haugen, Vidar Skaug, Suenori Chiku, Itaru Yamanaka, Yasuhito Arai, Shun-ichi Watanabe, Ikuo Sekine, Seishi Ogawa, Curtis C Harris, Hitoshi Tsuda, Teruhiko Yoshida, Jun Yokota, Tatsuhiro Shibata, KIF5B-RET fusions in lung adenocarcinoma Nature Medicine. ,vol. 18, pp. 375- 377 ,(2012) , 10.1038/NM.2644
Zhenfeng Zhang, Jae Cheol Lee, Luping Lin, Victor Olivas, Valerie Au, Thomas LaFramboise, Mohamed Abdel-Rahman, Xiaoqi Wang, Alan D Levine, Jin Kyung Rho, Yun Jung Choi, Chang-Min Choi, Sang-We Kim, Se Jin Jang, Young Soo Park, Woo Sung Kim, Dae Ho Lee, Jung-Shin Lee, Vincent A Miller, Maria Arcila, Marc Ladanyi, Philicia Moonsamy, Charles Sawyers, Titus J Boggon, Patrick C Ma, Carlota Costa, Miquel Taron, Rafael Rosell, Balazs Halmos, Trever G Bivona, Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer Nature Genetics. ,vol. 44, pp. 852- 860 ,(2012) , 10.1038/NG.2330
J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Janne, MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Science. ,vol. 316, pp. 1039- 1043 ,(2007) , 10.1126/SCIENCE.1141478
C. Gjerdrum, C. Tiron, T. Hoiby, I. Stefansson, H. Haugen, T. Sandal, K. Collett, S. Li, E. McCormack, B. T. Gjertsen, D. R. Micklem, L. A. Akslen, C. Glackin, J. B. Lorens, Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 107, pp. 1124- 1129 ,(2010) , 10.1073/PNAS.0909333107